These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 19138246

  • 21. Prolonged accumulation of high-dose methotrexate in a case with large liver cysts.
    Kawakami M, Omori H, Yamagami T, Soma T.
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):619-22. PubMed ID: 19319534
    [Abstract] [Full Text] [Related]

  • 22. Renal dysfunction during and after high-dose methotrexate.
    Green MR, Chamberlain MC.
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
    [Abstract] [Full Text] [Related]

  • 23. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
    Schwartz S, Borner K, Müller K, Martus P, Fischer L, Korfel A, Auton T, Thiel E.
    Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
    Gerber DE, Grossman SA, Batchelor T, Ye X.
    Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
    [Abstract] [Full Text] [Related]

  • 29. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F, Letrent SP, Sharma A.
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [Abstract] [Full Text] [Related]

  • 30. Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics.
    Sabot C, Debord J, Roullet B, Marquet P, Merle L, Lachatre G.
    Int J Clin Pharmacol Ther; 1995 Mar; 33(3):164-9. PubMed ID: 7599915
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis.
    Yang L, Wu H, de Winter BCM, Sheng CC, Qiu HQ, Cheng Y, Chen J, Zhao QL, Huang J, Jiao Z, Xie RX.
    Cancer Chemother Pharmacol; 2020 May; 85(5):881-897. PubMed ID: 32246190
    [Abstract] [Full Text] [Related]

  • 32. Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia.
    Zhang C, Zhai S, Yang L, Wu H, Zhang J, Ke X.
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):11-21. PubMed ID: 20040335
    [Abstract] [Full Text] [Related]

  • 33. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
    Isono T, Hira D, Morikochi A, Fukami T, Ueshima S, Nozaki K, Terada T, Morita SY.
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
    [Abstract] [Full Text] [Related]

  • 34. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK, Musuamba FT, Nyberg J, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq PE.
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.
    Debord J, Carpentier N, Sabot C, Bertin P, Marquet P, Treves R, Merle L, Lachâtre G.
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):227-30. PubMed ID: 9587050
    [Abstract] [Full Text] [Related]

  • 37. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia.
    Plard C, Bressolle F, Fakhoury M, Zhang D, Yacouben K, Rieutord A, Jacqz-Aigrain E.
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):609-20. PubMed ID: 17195068
    [Abstract] [Full Text] [Related]

  • 38. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type.
    Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T.
    J Clin Pharm Ther; 2009 Aug; 34(4):473-83. PubMed ID: 19583681
    [Abstract] [Full Text] [Related]

  • 39. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
    Mougenot P, Pinguet F, Fabbro M, Culine S, Poujol S, Astre C, Bressolle F.
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
    [Abstract] [Full Text] [Related]

  • 40. Population pharmacokinetic parameters of vancomycin in critically ill patients.
    Llopis-Salvia P, Jiménez-Torres NV.
    J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.